(GLPG) Galapagos - Ratings and Ratios
Rheumatoid, Arthritis, Psoriatic, Fibrosis, Therapy
GLPG EPS (Earnings per Share)
GLPG Revenue
Description: GLPG Galapagos
Galapagos NV ADR (GLPG) is a Belgian biotechnology company listed on NASDAQ. As a common stock, it represents ownership in the company. The biotechnology industry is known for its high-risk, high-reward profile, driven by innovation and R&D efforts.
To evaluate GLPGs performance, key financial metrics and KPIs are essential. The companys market capitalization stands at $2.2 billion, indicating a significant presence in the market. However, the P/E ratio is not available, likely due to negative earnings. The forward P/E ratio is 166.67, suggesting high growth expectations. Return on Equity (RoE) is -10.20%, indicating that the company is currently unprofitable.
Key economic drivers for GLPG include the success of its R&D pipeline, particularly in developing innovative treatments for various diseases. The companys financial performance is closely tied to the progress of its clinical trials, regulatory approvals, and eventual commercialization of its products. Investors should monitor news on clinical trial results, regulatory updates, and partnerships or collaborations that could impact the companys prospects.
To assess the stocks attractiveness, its crucial to analyze its trading activity and volatility. With an average daily trading volume of 355,898 shares, GLPG has a relatively liquid market. The stocks beta is -0.048, indicating a very low correlation with the overall market, which could be attractive for diversification purposes. However, the negative beta also suggests that the stock may not be a reliable hedge or may be influenced by company-specific factors.
From a trading perspective, GLPGs recent price action shows a stock price of $32.88, with short-term and long-term moving averages indicating a potential uptrend. The Average True Range (ATR) is 0.97, corresponding to a 2.95% daily price range, which can help traders gauge volatility. To make informed investment decisions, its essential to monitor these technical indicators and fundamental drivers closely.
GLPG Stock Overview
| Market Cap in USD | 2,078m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2005-05-06 |
GLPG Stock Ratings
| Growth Rating | -25.1% |
| Fundamental | 26.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -10.9% |
| Analyst Rating | 2.50 of 5 |
GLPG Dividends
Currently no dividends paidGLPG Growth Ratios
| Growth Correlation 3m | 61.3% |
| Growth Correlation 12m | 34.9% |
| Growth Correlation 5y | -94.8% |
| CAGR 5y | -11.28% |
| CAGR/Max DD 3y | -0.21 |
| CAGR/Mean DD 3y | -0.37 |
| Sharpe Ratio 12m | -0.47 |
| Alpha | 0.15 |
| Beta | 0.437 |
| Volatility | 26.72% |
| Current Volume | 121.8k |
| Average Volume 20d | 161.1k |
| Stop Loss | 31.2 (-3.3%) |
| Signal | 0.36 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-284.3m TTM) > 0 and > 6% of Revenue (6% = 16.5m TTM) |
| FCFTA -0.11 (>2.0%) and ΔFCFTA -0.62pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1035 % (prev 6445 %; Δ -5410 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -278.5m > Net Income -284.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.08 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (65.8m) change vs 12m ago -0.09% (target <= -2.0% for YES) |
| Gross Margin 52.33% (prev -113.3%; Δ 165.6pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 6.80% (prev 1.19%; Δ 5.60pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -101.6 (EBITDA TTM -102.3m / Interest Expense TTM 1.15m) >= 6 (WARN >= 3) |
Altman Z'' 4.30
| (A) 0.75 = (Total Current Assets 3.26b - Total Current Liabilities 403.0m) / Total Assets 3.82b |
| (B) -0.10 = Retained Earnings (Balance) -380.8m / Total Assets 3.82b |
| (C) -0.03 = EBIT TTM -117.0m / Avg Total Assets 4.05b |
| (D) -0.08 = Book Value of Equity -93.2m / Total Liabilities 1.17b |
| Total Rating: 4.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.22
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -71.95% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.29 = 2.46 |
| 5. Debt/Ebitda -7.56 = -2.50 |
| 6. ROIC - WACC (= -9.52)% = -11.90 |
| 7. RoE -10.20% = -1.70 |
| 8. Rev. Trend -4.35% = -0.33 |
| 9. EPS Trend -26.19% = -1.31 |
What is the price of GLPG shares?
Over the past week, the price has changed by -0.25%, over one month by -1.98%, over three months by +15.54% and over the past year by +5.56%.
Is Galapagos a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GLPG is around 29.72 USD . This means that GLPG is currently overvalued and has a potential downside of -7.87%.
Is GLPG a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 4
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the GLPG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.5 | -21% |
| Analysts Target Price | 25.5 | -21% |
| ValueRay Target Price | 32.2 | -0.2% |
Last update: 2025-09-05 04:44
GLPG Fundamental Data Overview
CCE Cash And Equivalents = 3.09b EUR (Cash And Short Term Investments, last quarter)
P/E Forward = 294.1176
P/S = 7.5411
P/B = 0.6655
Beta = -0.048
Revenue TTM = 275.6m EUR
EBIT TTM = -117.0m EUR
EBITDA TTM = -102.3m EUR
Long Term Debt = 771.5m EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 2.39m EUR (from shortTermDebt, last quarter)
Debt = 773.8m EUR (Calculated: Short Term 2.39m + Long Term 771.5m)
Net Debt = -63.2m EUR (from netDebt column, last quarter)
Enterprise Value = -558.9m EUR (1.76b + Debt 773.8m - CCE 3.09b)
Interest Coverage Ratio = -101.6 (Ebit TTM -117.0m / Interest Expense TTM 1.15m)
FCF Yield = -71.95% (FCF TTM -402.1m / Enterprise Value -558.9m)
FCF Margin = -145.9% (FCF TTM -402.1m / Revenue TTM 275.6m)
Net Margin = -103.1% (Net Income TTM -284.3m / Revenue TTM 275.6m)
Gross Margin = 52.33% ((Revenue TTM 275.6m - Cost of Revenue TTM 131.4m) / Revenue TTM)
Tobins Q-Ratio = 6.00 (Enterprise Value -558.9m / Book Value Of Equity -93.2m)
Interest Expense / Debt = 0.10% (Interest Expense 780.0k / Debt 773.8m)
Taxrate = 21.0% (US default)
NOPAT = -117.0m (EBIT -117.0m, no tax applied on loss)
Current Ratio = 8.08 (Total Current Assets 3.26b / Total Current Liabilities 403.0m)
Debt / Equity = 0.29 (Debt 773.8m / last Quarter total Stockholder Equity 2.64b)
Debt / EBITDA = -7.56 (Net Debt -63.2m / EBITDA -102.3m)
Debt / FCF = -1.92 (Debt 773.8m / FCF TTM -402.1m)
Total Stockholder Equity = 2.79b (last 4 quarters mean)
RoA = -7.45% (Net Income -284.3m, Total Assets 3.82b )
RoE = -10.20% (Net Income TTM -284.3m / Total Stockholder Equity 2.79b)
RoCE = -3.29% (Ebit -117.0m / (Equity 2.79b + L.T.Debt 771.5m))
RoIC = -4.20% (NOPAT -117.0m / Invested Capital 2.79b)
WACC = 5.32% (E(1.76b)/V(2.53b) * Re(7.63%)) + (D(773.8m)/V(2.53b) * Rd(0.10%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 26.80 | Cagr: 0.00%
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -402.1m)
EPS Correlation: -26.19 | EPS CAGR: -29.25% | SUE: -0.96 | # QB: 0
Revenue Correlation: -4.35 | Revenue CAGR: -23.46% | SUE: N/A | # QB: None
Additional Sources for GLPG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle